Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

PHASE3CompletedINTERVENTIONAL
Enrollment

429

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2013

Conditions
Carcinoid TumorMalignant Carcinoid Syndrome
Interventions
DRUG

Octreotide

Octreotide 30 mg intramuscularly (i.m.) every 28 days.

DRUG

Placebo

A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.

DRUG

Everolimus

A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.

Trial Locations (70)

1070

Novartis Investigative Site, Brussels

2217

Novartis Investigative Site, Kogarah

4029

Novartis Investigative Site, Herston

4101

Novartis Investigative Site, South Brisbane

10016

New York University Medical Center NYU Medical Center (2), New York

12206

New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Albany

13353

Novartis Investigative Site, Berlin

20100

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

20246

Novartis Investigative Site, Hamburg

23502

Virginia Oncology Associates VOA - Lake Wright, Norfolk

27710

Duke University Medical Center Dept. of Duke Cancer Center, Durham

28041

Novartis Investigative Site, Madrid

29615

Cancer Centers of the Carolinas CC of C -Eastside, Greenville

31059

Novartis Investigative Site, Toulouse

34298

Novartis Investigative Site, Montpellier

34471

Ocala Oncology Center Dept. of Ocala Oncology Center, Ocala

40138

Novartis Investigative Site, Bologna

40202

Norton Cancer Institute Clinical Research Program, Louisville

46202

Indiana University Dept.of IndianaUniv.CancerCtr, Indianapolis

46227

Central Indiana Cancer Centers CICC - South, Indianapolis

52242

University of Iowa Medical Center Internal Medicine, Iowa City

53792

University of Wisconsin / Paul P. Carbone Comp Cancer Center GI Oncology Research Center, Madison

55905

Mayo Clinic - Rochester Division of Hematology, Rochester

56126

Novartis Investigative Site, Pisa

59020

Novartis Investigative Site, Lille

60714

Cancer Care and Hematology Specialists of Chicagoland Niles, Niles

63110

Washington University School Of Medicine-Siteman Cancer Ctr Division of Oncology, St Louis

63141

The Center for Cancer Care and Research, St Louis

66160

University of Kansas Cancer Center Deptof Uof Kansas CancerCenter, Kansas City

66210

Kansas City Cancer Center KCCC Business Office, Overland Park

67098

Novartis Investigative Site, Strasbourg

70112

LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2), New Orleans

72205

Hematology Oncology Services of Arkansas, Little Rock

72703

Highlands Oncology Group The Center for Chest Care, Fayetteville

75246

Sammons Cancer Center - Texas Oncology Sammons Cancer Center (SC), Dallas

75702

Tyler Cancer Center, Tyler

75908

Novartis Investigative Site, Paris

76104

Texas Oncology, P.A. Forth Worth -- 12th Avenue, Fort Worth

77030

University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston

78405

South Texas Institute of Cancer S. Tex Inst.- Corpus Christi, Corpus Christi

78731

Texas Oncology, P.A. Central Austin Cancer Center, Austin

80045

University of Colorado Dept. of Univ. of Colorado, Aurora

80218

Rocky Mountain Cancer Centers Dept of Rocky Mountain (2), Denver

85719

University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2), Tucson

90048

Cedars Sinai Medical Center SC-2, Los Angeles

90095

University of California at Los Angeles UCLA New SC Address, Los Angeles

92118

Novartis Investigative Site, Clichy Cédex

92801

Pacific Cancer Medical Center, Inc., Anaheim

94805

Novartis Investigative Site, Villejuif

98684

Northwest Cancer Specialists Compass Oncology -BKM, Vancouver

06360

Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO, Norwich

06489

Cancer Centers of Connecticut Southington Location, Southington

06902

Hematology Oncology PC Dept.of Hematology Oncology(2), Stamford

03756

Dartmouth Hitchcock Medical Center Medical Oncology, Lebanon

19111-2497

Fox Chase Cancer Center, Philadelphia

N6A 4L6

Novartis Investigative Site, London

M5G 2M9

Novartis Investigative Site, Toronto

H1T 2M4

Novartis Investigative Site, Montreal

H2X 1P1

Novartis Investigative Site, Montreal

128 08

Novartis Investigative Site, Prague

261 95

Novartis Investigative Site, Příbram

FIN-00290

Novartis Investigative Site, Helsinki

GR 11527

Novartis Investigative Site, Athens

06132

Novartis Investigative Site, Perugia

9713 GZ

Novartis Investigative Site, Groningen

3015 CE

Novartis Investigative Site, Rotterdam

813 69

Novartis Investigative Site, Bratislava

SE-751 85

Novartis Investigative Site, Uppsala

RG24 9NA

Novartis Investigative Site, Basingstoke

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY